Hiroyuki Kawai

This inventor holds 11 USPTO granted patents and 10 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignee: Oric Pharmaceuticals, Inc.. Active years: 2021-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hiroyuki Kawai. Retrieved from https://idiyas.com/inventor/hiroyuki-kawai-m9baskms

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 10)

% Patents Active = 90.9

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 2 (Patent Applications = 1)

Average Co-Inventor Count = 14.2

ph-index = 3

Forward Citations = 26(Granted Patents)

Company Filing History:

11 out of 20

Oric Pharmaceuticals, Inc.

patents

Years Active: 2021-2026

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12577272 - CD73 inhibitors (2026-03-17),

2. 12544391 - CD73 inhibitors (2026-02-10),

3. 12454544 - CD73 inhibitors (2025-10-28),

4. 12312339 - Polo like kinase 4 inhibitors (2025-05-27),

5. 12018043 - CD73 inhibitors (2024-06-25),

6. 11858915 - Polo like kinase 4 inhibitors (2024-01-02),

7. 11807658 - CD73 inhibitors (2023-11-07),

8. 11530236 - CD73 inhibitors (2022-12-20),

9. 11325938 - CD73 inhibitors (2022-05-10),

10. 11130778 - CD73 inhibitors (2021-09-28),

11. 11028120 - CD73 inhibitors (2021-06-08),

Title: Hiroyuki Kawai: Innovator in Cancer Treatment

Introduction

Hiroyuki Kawai is a prominent inventor based in Pacifica, California, known for his significant contributions to the field of cancer treatment. With a total of eight patents to his name, Kawai has made remarkable strides in developing innovative pharmaceutical compounds.

Latest Patents

Among his latest patents are the Polo Like Kinase 4 inhibitors. These compounds, represented by Formula (I), are designed to inhibit Polo Like Kinase 4 (PLK4). The patent also includes pharmaceutical compositions that comprise these compounds and methods for treating cancer in patients. Another notable patent involves CD73 inhibitors, which are useful for treating cancer, infections, and neurodegenerative diseases. These advancements highlight Kawai's commitment to addressing critical health challenges.

Career Highlights

Kawai has worked with several notable companies, including Oric Pharmaceuticals, Inc. and Halosource, Inc. His experience in these organizations has allowed him to refine his expertise in pharmaceutical development and innovation.

Collaborations

Throughout his career, Kawai has collaborated with talented individuals such as Xiaohui Du and Jared Moore. These partnerships have contributed to the success of his projects and the advancement of his research.

Conclusion

Hiroyuki Kawai's work in developing innovative cancer treatments through his patents demonstrates his dedication to improving healthcare. His contributions continue to impact the field positively, showcasing the importance of innovation in medicine.

Profile summary based on public USPTO records.